Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5...
35 insider purchases on record · latest filing 2024-11-22.
Insiders have also filed 62 sale transactions at INBX.